Cullin 7 Polyclonal Antibody, Cy5.5 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bs-9127R-Cy5.5 |
| Product Name | Cullin 7 Polyclonal Antibody, Cy5.5 Conjugated |
| Applications |
WB
IF
|
| Reactivity | Human, Mouse, Rat |
| Specifications | |
| Conjugation | Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human Cullin 7 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 9820 |
| Synonyms | CUL-7; CUL7; CUL7_HUMAN; Cullin-7; dJ20C7.5; KIAA0076. |
| Background | Component of a probable SCF-like E3 ubiquitin-protein ligase complex, which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Probably plays a role in the degradation of proteins involved in endothelial proliferation and/or differentiation (By similarity). Seems not to promote polyubiquitination and proteasomal degradation of TP53. In vitro, complexes of CUL7 with either CUL9 or FBXW8 or TP53 contain E3 ubiquitin-protein ligase activity.Involvement in disease: Defects in CUL7 are the cause of 3M syndrome type 1 (3M1). An autosomal recessive disorder characterized by severe pre- and postnatal growth retardation, facial dysmorphism, large head circumference, and normal intelligence and endocrine function. Skeletal changes include long slender tubular bones and tall vertebral bodies. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF | IHC-P1:50-200 |